We were exploring ways of developing peptides that bind selectively, and we were very successful at that, but then we confronted the problem that our short, 23-residue peptides are not promising therapeutic candidates primarily because they cannot get into cells, Keating says
[ref] BPC-157 resolved an insurmountable deleterious course to achieve quadracept muscle to bone reattachment in rats
It covers glutathione and the full IV nutrient toolkit: biochemistry, dosing, IV-push technique, compounding and compliance, patient selection, safety, and honest benefit communication
First, there is the issue of dosing
If you are a tested athlete, the Wolverine Stack is completely off-limits